J Rheumatol
-
To determine the prevalence of muscular or myofascial temporomandibular disorders (TMD) in fibromyalgia (FM) and the prevalence of FM in TMD; and to determine which characteristics best distinguish the 2 disorders. ⋯ TMD is a local disorder and FM a generalized disorder, and there is less evidence of distress in those with TMD. TMD is a separate disorder from FM, but many patients with FM have TMD symptoms.
-
To evaluate the validity and reliability of recordings of pain location among patients with pain from 2 different sources, using the McGill Pain Map (MPM). ⋯ Recordings of pain location using the MPM are valid and reliable. The MPM is a valuable instrument for studies of the distribution of pain in populations.
-
The classification of widespread pain, proposed by the American College of Rheumatology (ACR) for use in the clinic as a screen for fibromyalgia, as described, does not require truly widespread pain. Studies considering the epidemiology of widespread pain per se may therefore require a definition with greater face validity, which might also show enhanced associations with other physical and psychological measures. We aimed to develop a more coherent definition of widespread pain for use in epidemiological studies and to compare performance in identifying individuals with significant morbidity. ⋯ A redefinition of widespread pain has produced a group of subjects whose pain is (a) likely to be more "widespread" and (b) is associated more strongly with factors such as psychological disturbance, fatigue, sleep problems, and tender points, and may be more appropriate in epidemiological studies.
-
To evaluate the predictors of improvement at 2 years in subjects with chronic widespread pain ascertained from a community survey. ⋯ Chronic widespread pain in the community has a generally good prognosis. However, those with additional symptoms associated with the fibromyalgia syndrome were more likely still to have chronic widespread pain 2 years later.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis.
To compare the efficacy and tolerability of lornoxicam and diclofenac in the treatment of patients with osteoarthritis (OA) over 12 weeks and to assess the efficacy and tolerability of lornoxicam over a followup period of 40 weeks. ⋯ Lornoxicam 4 mg tid and 8 mg bid were as effective as diclofenac 50 mg tid for the treatment of OA. There was no significant difference in tolerability of these regimens. Thus, lornoxicam appears to be a useful therapeutic alternative to diclofenac in patients with OA.